Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2007

View Archived Issues

Novel therapeutic agents for Alzheimer's disease reported in recent AstraZeneca patent

Recent Takeda patent reports novel tachykinin NK1 antagonists

Cudraflavanone A antitumor mechanism identified

TZB-30878 shows potential for IBS in preclinical studies

Abbott continues to develop novel multitargeted RTK inhibitors

Oral efficacy of new MIF inhibitor in animal models of inflammatory diseases

Lorus Therapeutics reports year end results for 2007

AGI Therapeutics licenses compound with potential for GI-related applications

Takeda's TAK-536 enters phase II for treatment of hypertension in Japan

Promising phase II clinical trial results for Reviroc

Plans delayed for phase III study of bremelanotide for ED

YM BioSciences to begin phase II trial of nimotuzumab for DIPG

FDA approves Omrix's BLA for thrombin stand alone topical Evithrom

Novel non-nucleoside HIV reverse transcriptase inhibitors profiled at Roche

Optimization of natural Chinese medicine leads to potential treatment for alcohol addiction

Cardiome Pharma and Astellas Pharma announce PDUFA extension

Karo Bio provides update of internal projects

Positive phase II trial results for Histalean in obese women under 50

Potential efficacy of amphotericin B-containing hydrogel against intravascular catheter infections

Pfizer discloses novel antibacterial agents in recent patents

Novel agents for HCV infection reported in recent Wyeth and GSK patents

First patient dosed in Opko's pivotal phase III bevasiranib trial for wet AMD

Sunesis reorganizes drug development focus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...